The 36-month beta value for LUCD is at 1.36. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for LUCD is 24.38M, and currently, shorts hold a 2.18% of that float. The average trading volume for LUCD on February 26, 2025 was 519.08K shares.
LUCD) stock’s latest price update
Lucid Diagnostics Inc (NASDAQ: LUCD)’s stock price has plunge by 1.76relation to previous closing price of 1.42. Nevertheless, the company has seen a -9.12% plunge in its stock price over the last five trading sessions. prnewswire.com reported 2025-02-25 that NEW YORK, Feb. 25, 2025 /PRNewswire/ — Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has received written notification from the Listings Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. As previously disclosed, the Company was notified by Nasdaq that it was not in compliance with this listing rule because it failed to maintain a minimum closing bid price of its common stock of $1.00 per share for 30 consecutive business days.
LUCD’s Market Performance
Lucid Diagnostics Inc (LUCD) has seen a -9.12% fall in stock performance for the week, with a 62.82% gain in the past month and a 44.64% surge in the past quarter. The volatility ratio for the week is 15.71%, and the volatility levels for the past 30 days are at 10.95% for LUCD. The simple moving average for the past 20 days is 16.89% for LUCD’s stock, with a 62.84% simple moving average for the past 200 days.
Analysts’ Opinion of LUCD
Many brokerage firms have already submitted their reports for LUCD stocks, with Ascendiant Capital Markets repeating the rating for LUCD by listing it as a “Buy.” The predicted price for LUCD in the upcoming period, according to Ascendiant Capital Markets is $16 based on the research report published on December 27, 2021 of the previous year 2021.
Needham, on the other hand, stated in their research note that they expect to see LUCD reach a price target of $17. The rating they have provided for LUCD stocks is “Buy” according to the report published on November 08th, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to LUCD, setting the target price at $21 in the report published on November 08th of the previous year.
LUCD Trading at 46.38% from the 50-Day Moving Average
After a stumble in the market that brought LUCD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.51% of loss for the given period.
Volatility was left at 10.95%, however, over the last 30 days, the volatility rate increased by 15.71%, as shares surge +58.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +86.89% upper at present.
During the last 5 trading sessions, LUCD fell by -10.38%, which changed the moving average for the period of 200-days by +50.00% in comparison to the 20-day moving average, which settled at $1.2352. In addition, Lucid Diagnostics Inc saw 76.50% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for LUCD
Current profitability levels for the company are sitting at:
- -10.77 for the present operating margin
- -0.85 for the gross margin
The net margin for Lucid Diagnostics Inc stands at -10.7. The total capital return value is set at -5.41. Equity return is now at value -1007.83, with -160.52 for asset returns.
Based on Lucid Diagnostics Inc (LUCD), the company’s capital structure generated 0.67 points at debt to capital in total, while cash flow to debt ratio is standing at -3.39. The debt to equity ratio resting at 2.06. The interest coverage ratio of the stock is -1504.37.
Currently, EBITDA for the company is -49.75 million with net debt to EBITDA at 0.03. When we switch over and look at the enterprise to sales, we see a ratio of 20.13. The receivables turnover for the company is 107.41for trailing twelve months and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.18.
Conclusion
In conclusion, Lucid Diagnostics Inc (LUCD) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
